Bhagat Vishal, Javle Milind, Yu Jihnhee, Agrawal Aarti, Gibbs John F, Kuvshinoff Boris, Nava Enriquetta, Iyer Renuka
Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.
Int J Gastrointest Cancer. 2006;37(1):27-34. doi: 10.1385/IJGC:37:1:27.
Combined hepatocholangiocarcinoma (CHCC) is an infrequent primary hepatic malignancy with no clearly defined diagnostic criteria, poorly studied natural history, and no guidelines regarding therapy. In this study we attempted to address this need and review our experience.
We performed a retrospective review of all CHCC cases at our institute over the last 10 yr. Eight cases were identified; histological and immunohistochemical criteria used for diagnosis were defined. Patients characteristics were: median age 65 yr (range 47-80); five females; risk factors-cholelithiasis (n = 4) and cirrhosis due to chronic viral hepatitis B and C (n = 1). Abdominal pain (n = 6), hepatomegaly (n = 4), and elevated CA 19-9 >40 U/mL (n = 4/5) were frequent. Early TNM stage (I and II) compared with advanced disease (III and IV) correlated with higher overall survival on univariate analyses [37 and 6 mo respectively (p = 0.011)]. Median overall survival was significantly higher in patients who underwent potentially curative resection (23 mo, range 4-48+) compared with patients who underwent non-surgical therapies such as transcatheter arterial chemoembolization and chemotherapy (2 mo, range 1-8) (p = 0.0357, one-sided exact log-rank test).
Chronic inflammation and cirrhosis may play a role in pathogenesis of CHCC. Surgical resection and early stage at diagnosis predict longer survival.
肝内胆管癌(CHCC)是一种罕见的原发性肝脏恶性肿瘤,其诊断标准尚不明确,自然病史研究较少,且缺乏治疗指南。在本研究中,我们试图满足这一需求并回顾我们的经验。
我们对本机构过去10年的所有CHCC病例进行了回顾性研究。共识别出8例病例;定义了用于诊断的组织学和免疫组化标准。患者特征为:中位年龄65岁(范围47 - 80岁);5名女性;危险因素包括胆结石(n = 4)以及慢性乙型和丙型病毒性肝炎导致的肝硬化(n = 1)。常见症状有腹痛(n = 6)、肝肿大(n = 4)以及CA 19 - 9升高>40 U/mL(n = 4/5)。单因素分析显示,早期TNM分期(I期和II期)与晚期疾病(III期和IV期)相比,总生存期更长[分别为37个月和6个月(p = 0.011)]。与接受经动脉化疗栓塞和化疗等非手术治疗的患者(2个月,范围1 - 8个月)相比,接受潜在根治性切除的患者中位总生存期显著更高(23个月,范围4 - 48 +个月)(p = 0.0357,单侧精确对数秩检验)。
慢性炎症和肝硬化可能在CHCC的发病机制中起作用。手术切除和诊断时的早期阶段预示着更长的生存期。